Compare Schlumberger NV (SLB) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs BIO-TECHNE Corp — how do they compare? Schlumberger NV trades at $48.97 (market cap $71.18B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Schlumberger NV is far larger — about 6.3× BIO-TECHNE Corp's market cap, and Schlumberger NV pays the higher dividend (2.46%). Which is the better fit depends on your goals — on Pluang, investors hold Schlumberger NV for 99 Days and BIO-TECHNE Corp for 63 Days on average.
| SLB | TECH | |
|---|---|---|
Market Cap | $71.18B | $11.37B |
Volume | 14,872,321 | 3,153,511 |
Sector | Energy | Health |
52-Week High | $60.10 | $72.61 |
52-Week Low | $31.72 | $43.31 |
Typical Hold Time | 99 Days | 63 Days |
Enterprise Value | $79.91B | $11.40B |
Dividend Yield | 2.46% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $47.96, down 4.08% in the last session, with technical indicators showing bearish momentum. The company maintains strong fundamentals with consistent earnings beats and a robust $35.71B revenue base, though 2025 net income declined to $3.37B. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility, supporting analyst optimism with an 84.85% buy rating and $64.58 consensus price target.
SLB presents a compelling value opportunity with significant upside to analyst targets, driven by expanding international contracts and solid cash flow generation. Key risks include oil price volatility and execution challenges in new projects. The stock's current technical weakness may offer an attractive entry point for long-term investors seeking energy sector exposure.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
